- Home
- GNPX vs LGMK Comparison
GNPX vs LGMK Comparison
Compare GNPX & LGMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- LGMK
- Stock Information
- Founded
- GNPX 2009
- LGMK 2011
- Country
- GNPX United States
- LGMK United States
- Employees
- GNPX N/A
- LGMK 32
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- LGMK Industrial Specialties
- Sector
- GNPX Health Care
- LGMK Health Care
- Exchange
- GNPX Nasdaq
- LGMK Nasdaq
- Market Cap
- GNPX 7.5M
- LGMK 6.6M
- IPO Year
- GNPX 2018
- LGMK N/A
- Fundamental
- Price
- GNPX $0.29
- LGMK $0.00
- Analyst Decision
- GNPX
- LGMK
- Analyst Count
- GNPX 0
- LGMK 0
- Target Price
- GNPX N/A
- LGMK N/A
- AVG Volume (30 Days)
- GNPX 1.8M
- LGMK 141.5M
- Earning Date
- GNPX 05-12-2025
- LGMK 05-15-2025
- Dividend Yield
- GNPX N/A
- LGMK N/A
- EPS Growth
- GNPX N/A
- LGMK N/A
- EPS
- GNPX N/A
- LGMK N/A
- Revenue
- GNPX N/A
- LGMK $9,882,728.00
- Revenue This Year
- GNPX N/A
- LGMK $2.57
- Revenue Next Year
- GNPX N/A
- LGMK $99,999,400.00
- P/E Ratio
- GNPX N/A
- LGMK N/A
- Revenue Growth
- GNPX N/A
- LGMK 1.56
- 52 Week Low
- GNPX $0.22
- LGMK $0.01
- 52 Week High
- GNPX $3.97
- LGMK $24.00
- Technical
- Relative Strength Index (RSI)
- GNPX 50.37
- LGMK 20.42
- Support Level
- GNPX $0.26
- LGMK $0.01
- Resistance Level
- GNPX $0.37
- LGMK $0.01
- Average True Range (ATR)
- GNPX 0.04
- LGMK 0.00
- MACD
- GNPX 0.00
- LGMK 0.00
- Stochastic Oscillator
- GNPX 35.04
- LGMK 8.33
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.